MetaVia (MTVA) Curent Deferred Tax Liability (2015 - 2016)
MetaVia's (MTVA) quarterly Curent Deferred Tax Liability came in at -$10000.0 in Q4 2016, little changed YoY from -$10000.0 in Q1 2016, and little changed on a QoQ basis from -$10000.0 in Q4 2015.
MetaVia (MTVA) Curent Deferred Tax Liability (2015 - 2016) Analysis & Trends
MetaVia (MTVA) has 2 years of Curent Deferred Tax Liability data on file, last reported at -$10000.0 in Q4 2016.
- Quarterly Curent Deferred Tax Liability changed 0.0% year-over-year to -$10000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$10000.0 (changed 0.0% YoY) and the FY2016 annual result came in at -$10000.0, changed 0.0% from the prior year.
- Curent Deferred Tax Liability held at -$10000.0 in Q4 2016, from -$10000.0 in the prior quarter.
- In the past five years, Curent Deferred Tax Liability ranged from a high of -$10000.0 in Q4 2015 to a low of -$10000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -10,000.00 |
| Dec 31, 2016 | -10,000.00 |
| Dec 31, 2015 | -10,000.00 |
| Dec 31, 2015 | -10,000.00 |